PIRAMAL PHARMA Financial Statement Analysis
|
||
The Revenues of PIRAMAL PHARMA have increased by 3.87% YoY .
The Earnings Per Share (EPS) of PIRAMAL PHARMA has decreased by Negative YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
PIRAMAL PHARMA Last 5 Annual Financial Results
[BOM: 543635|NSE : PPLPHARMA]
Consolidated | Mar2023 | Mar2022 | Mar2021 |
---|---|---|---|
Revenues | ₹6,559 Cr | ₹6,315 Cr | ₹6,315 Cr |
Expenses | ₹5,609 Cr | ₹4,887 Cr | ₹4,887 Cr |
Operating Profit (Excl OI) | ₹950 Cr | ₹1,428 Cr | ₹1,428 Cr |
Other Income | ₹276 Cr | ₹164 Cr | ₹164 Cr |
Interest | ₹198 Cr | ₹163 Cr | ₹163 Cr |
Depreciation | ₹586 Cr | ₹545 Cr | ₹545 Cr |
Profit Before Tax | ₹485 Cr | ₹949 Cr | ₹949 Cr |
Profit After Tax | ₹376 Cr | ₹835 Cr | ₹835 Cr |
Consolidated Net Profit | ₹376 Cr | ₹835 Cr | ₹835 Cr |
Earnings Per Share (Rs) | ₹-1.56 | ₹3.17 | ₹8.40 |
PAT Margin (%) | -2.30 | 5.15 | 13.22 |
ROE(%) | -2.77 | 6.11 | 14.90 |
ROCE(%) | 1.95 | 7.10 | 13.06 |
Total Debt/Equity(x) | 0.81 | 0.60 | 0.52 |
Key Financials |
||
Market Cap | : | ₹ 18,824.9 Cr |
Revenue (TTM) | : | ₹ 7,782.4 Cr |
Net Profit(TTM) | : | ₹ -88.6 Cr |
EPS (TTM) | : | ₹ -0.7 |
P/E (TTM) | : | - |
Industry Peers & Returns | 1W | 1M | 1Y |
PIRAMAL PHARMA | 0.7% | 17.3% | 102.5% |
SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
CIPLA | 4.1% | -4.8% | 55.6% |
DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
MANKIND PHARMA | 1.3% | 7% | NA |
TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
LUPIN | 0.6% | 0.5% | 127.2% |
PIRAMAL PHARMA Revenues
[BOM: 543635|NSE : PPLPHARMA]
Y-o-Y | 3.87 % |
5 Yr CAGR | 1.92 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹6,559 Cr | 3.87 | |
Mar2022 | ₹6,315 Cr | 0.00 | |
Mar2021 | ₹6,315 Cr | - |
PIRAMAL PHARMA Operating Profit
[BOM: 543635|NSE : PPLPHARMA]
Y-o-Y | -33.50 % |
5 Yr CAGR | -18.45 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹950 Cr | -33.50 | |
Mar2022 | ₹1,428 Cr | 0.00 | |
Mar2021 | ₹1,428 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -35.96 % |
5 Yr CAGR | -19.97 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 14.48% | -35.96 | |
Mar2022 | 22.61% | 0.00 | |
Mar2021 | 22.61% | - |
PIRAMAL PHARMA Profit After Tax
[BOM: 543635|NSE : PPLPHARMA]
Y-o-Y | -54.98 % |
5 Yr CAGR | -32.90 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹376 Cr | -54.98 | |
Mar2022 | ₹835 Cr | 0.00 | |
Mar2021 | ₹835 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | Negative |
5 Yr CAGR | Negative |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | -2.3 % | Negative | |
Mar2022 | 5.15 % | -61.04 | |
Mar2021 | 13.22 % | - |
PIRAMAL PHARMA Earnings Per Share (EPS)
[BOM: 543635|NSE : PPLPHARMA]
Y-o-Y | Negative |
5 Yr CAGR | Negative |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹-1.56 | Negative | |
Mar2022 | ₹3.17 | -62.26 | |
Mar2021 | ₹8.40 | - |
PIRAMAL PHARMA Return on Capital Employed (ROCE)
[BOM: 543635|NSE : PPLPHARMA]
Y-o-Y | -72.54 % |
5 Yr CAGR | -61.36 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 1.95% | -72.54 | |
Mar2022 | 7.1% | -45.64 | |
Mar2021 | 13.06% | - |
PIRAMAL PHARMA Share Price vs Sensex
Current Share Price | : | ₹142.3 |
Current MarketCap | : | ₹ 18,824.9 Cr |
Updated EOD on | : | Apr 26,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
PIRAMAL PHARMA | 0.7% |
17.3% |
102.5% |
SENSEX | 0.9% |
1.5% |
23.6% |
PIRAMAL PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE 250 SMALLCAP | 4.1% | 11.8% | 66.8% |
S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
S&P BSE SMALL CAP | 4% | 11.6% | 67.3% |
S&P BSE 400 MIDSMALLCAP | 3.8% | 9.1% | 62% |
S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY FREE SMALL 100 | 4.4% | 13.5% | 81.2% |
NIFTY SMALLCAP250 | 4.3% | 12.6% | 73.2% |
NIFTY MID SMALL400 | 3.9% | 9.6% | 64.8% |
NIFTY SMALLCAP 50 | 3.4% | 13.4% | 83.7% |
NIFTY500 MULTICAP 50:25:25 | 2.8% | 6.7% | 49.4% |
You may also like the below Video Courses
FAQ about PIRAMAL PHARMA Financials
How the annual revenues of PIRAMAL PHARMA have changed ?
The Revenues of PIRAMAL PHARMA have increased by 3.87% YoY .
How the Earnings per Share (EPS) of PIRAMAL PHARMA have changed?
The Earnings Per Share (EPS) of PIRAMAL PHARMA has decreased by Negative YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs